AstraZeneca India Pharma on Thursday said it has received approval from the government authority for the import, sale, and distribution of a medication used in treating non-small cell lung cancer ...

AstraZeneca's AZN short percent of float has risen 50.0% since its last report. The company recently reported that it has 7.34 million shares sold short , which is 0.24% of all regular shares that ...

AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 conference, held in Chicago, Illinois from 30 May to 3 June. The SERENA-6 trial ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.

AstraZeneca, Waltham, MA. View all articles by this author. Matthew Steven Davids. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. View all articles by this author. Notes.

Open-label, single-arm, single-center phase 1b/2 clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

(Funded by AstraZeneca; MATTERHORN ClinicalTrials.gov number, NCT04592913.) Notes This article was published on June 1, 2025, and updated on June 27, 2025, at NEJM.org.

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a deal.